Article Text

PDF
Risk prediction for severe osteoarthritis
  1. Georg Schett1,
  2. Jochen Zwerina1,
  3. Roland Axmann1,
  4. Johann Willeit2,
  5. Kiechl Stefan2
  1. 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
  2. 2Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
  1. Correspondence to Georg Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen 91054, Germany; georg.schett{at}uk-erlangen.de

Statistics from Altmetric.com

Osteoarthritis (OA) is one of the most frequent musculoskeletal diseases worldwide and is associated with a high burden of disease causing disability and considerable socioeconomic costs. In the USA, 200 000 patients undergo total hip replacement surgery annually as a consequence of joint failure owing to severe OA.1 The pharmacotherapy of advanced OA is limited to symptomatic treatment to obtain pain relief. To date, no drugs are available which allow rebuilding of damaged cartilage,2 and this may not change during the next few years, reinforcing the relevance of targeted interventions in early OA or even before the development of symptoms. As a consequence, clinicians have the challenging task of identifying those …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.